Trials / Unknown
UnknownNCT03675750
Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Shanghai Mental Health Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic drugs and the effects of the duration of hyperprolactinemia on bone metabolism in schizophrenia patients.
Detailed description
Hyperprolactinemia is a common adverse effect of antipsychotic drugs. Studies have shown that hyperprolactinemia may affect bone metabolism through direct and indirect effects and increase the risk of osteoporosis and fracture.The investigators assess the duration, the severity of hyperprolactinemia and its effects on bone metabolism in schizophrenics taking antipsychotic drugs through analyzing the correlation between prolactin levels and biochemical markers of bone metabolism and the correlation between the duration of hyperprolactinemia and abnormal bone metabolism. Meanwhile, the investigators aims to obtain the boundary value of prolactin levels in patients with abnormal bone metabolism.
Conditions
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2020-04-30
- Completion
- 2020-10-31
- First posted
- 2018-09-18
- Last updated
- 2019-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03675750. Inclusion in this directory is not an endorsement.